Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the breast cancer (CaB) drug market will exceed $6 billion in 2012, up from $2.7 billion in 2002. According to the new Pharmacor study entitled Breast Cancer, the CaB drug market is composed of two therapeutic groups: chemotherapy (including immunotherapy), and hormone therapy. The performance of the hormone therapy market between 2002 and 2007 will be particularly strong, showing 14.6% growth.
The study also finds that many new developments for CaB therapies have become disappointments. Several classes of novel agents (e.g., matrix metalloproteinase inhibitors, multidrug resistance inhibitors, antisense oligonucleotides) have failed to fulfill their promise to date. However, clinicians express optimism about epothilones.
"The one bright spot in the otherwise disappointing drug development for CaB is the epothilones, a class of agents closely related to taxanes but with several potential advantages that could translate into significant market success," said Andrew Paramore, analyst at Decision Resources. "The most advanced agents in this class are Bristol-Myers Squibb's BMS-247550 in Phase II and BMS-310705 in Phase I, Novartis's EPO-906 in Phase II, and Kosan Bioscience's epothilone D in Phase I."
About Breast Cancer
CaB is the most common cancer in women and the second-most common cause of malignancy-related death worldwide. Although the incidence of CaB is rising in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), primarily because of the growing number of elderly women, more women are surviving the disease and even those who are not cured are living longer.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Breast Cancer is an Onkos study.
About Decision Resources
Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/